-
EP3328363
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3328363
| EP3328363 - COMPOSITIONS AND METHODS FOR IMMUNOMODULATION [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 10.07.2020 Database last updated on 19.10.2024 | |
| Former | Request for examination was made Status updated on 04.05.2018 | ||
| Former | The international publication has been made Status updated on 11.02.2017 | Most recent event Tooltip | 10.07.2020 | Application deemed to be withdrawn | published on 12.08.2020 [2020/33] | Applicant(s) | For all designated states Tarveda Therapeutics, Inc. 134 Coolidge Avenue Watertown, MA 02472 / US | [2018/23] | Inventor(s) | 01 /
KADIYALA, Sudhakar 40 Hagen Road Newton, Massachusetts 02459 / US | 02 /
WARD, Donna T. 142A Main Street Groton, Massachusetts 01450 / US | [2018/23] | Representative(s) | Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | [2018/23] | Application number, filing date | 16833606.3 | 29.07.2016 | [2018/23] | WO2016US44705 | Priority number, date | US201562199422P | 31.07.2015 Original published format: US 201562199422 P | US201662332838P | 06.05.2016 Original published format: US 201662332838 P | [2018/23] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017023749 | Date: | 09.02.2017 | Language: | EN | [2017/06] | Type: | A1 Application with search report | No.: | EP3328363 | Date: | 06.06.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 09.02.2017 takes the place of the publication of the European patent application. | [2018/23] | Search report(s) | International search report - published on: | US | 09.02.2017 | (Supplementary) European search report - dispatched on: | EP | 23.07.2019 | Classification | IPC: | A61K9/14, A61K39/00, C12N15/115, A61P35/00, A61P37/04, A61K47/69, A61K47/68, C07K16/46, C07K16/30, C07K16/28, C07K16/24, C07K16/22, A61K41/00, A61K39/39 | [2019/13] | CPC: |
A61K39/39 (EP,US);
A61K47/6881 (US);
A61K41/0042 (US);
A61K47/6843 (US);
A61K47/6845 (US);
A61K47/6849 (US);
A61K47/6851 (US);
A61K47/6879 (US);
A61K47/6883 (EP,US);
A61K47/6889 (US);
A61K47/6933 (EP,US);
A61K47/6935 (US);
A61K47/6937 (US);
A61P35/00 (EP,US);
A61P37/04 (EP,US);
C07K16/22 (US);
C07K16/244 (US);
C07K16/2818 (EP,US);
C07K16/2866 (US);
C07K16/30 (US);
C07K16/468 (US);
A61K2039/505 (EP,US);
A61K2039/55516 (EP,US);
C07K2317/31 (US);
C07K2317/622 (EP,US);
C07K2317/75 (US);
C07K2317/76 (US);
|
| Former IPC [2018/23] | A61K9/14, A61K39/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/23] | Title | German: | ZUSAMMENSETZUNGEN UND VERFAHREN ZUR IMMUNMODULATION | [2018/23] | English: | COMPOSITIONS AND METHODS FOR IMMUNOMODULATION | [2018/23] | French: | COMPOSITIONS ET MÉTHODES D'IMMUNOMODULATION | [2018/23] | Entry into regional phase | 16.02.2018 | National basic fee paid | 16.02.2018 | Search fee paid | 16.02.2018 | Designation fee(s) paid | 16.02.2018 | Examination fee paid | Examination procedure | 16.02.2018 | Amendment by applicant (claims and/or description) | 16.02.2018 | Examination requested [2018/23] | 16.02.2018 | Date on which the examining division has become responsible | 20.02.2020 | Application deemed to be withdrawn, date of legal effect [2020/33] | 30.03.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2020/33] | Fees paid | Renewal fee | 27.07.2018 | Renewal fee patent year 03 | 29.07.2019 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI]WO2010144295 (UNIV MIAMI [US], et al) [X] 1,2 * abstract, [0004]-[0008], examples 1 and 2, Fig. 1-7 and claims * [I] 3,4,8-15; | [XI] - E. GILBOA ET AL, "Use of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors", CLINICAL CANCER RESEARCH, US, (20130301), vol. 19, no. 5, doi:10.1158/1078-0432.CCR-12-2067, ISSN 1078-0432, pages 1054 - 1062, XP055553699 [X] 1,2 * abstract, paragraph bridging p. 1058 to p. 1059 - p. 1061 right-hand column last full paragraph and fig. 4 and 5 * [I] 3,4,8-15 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-12-2067 | [XI] - DEWAN MD SAKIB HOSSAIN ET AL, "The aptamer-siRNA conjugates: reprogramming T cells for cancer therapy", THERAPEUTIC DELIVERY, GB, (20150101), vol. 6, no. 1, doi:10.4155/tde.14.92, ISSN 2041-5990, pages 1 - 4, XP055556134 [X] 2-4,8-10,13,14 * abstract, p. 2977 right-hand column first full paragraph - p. 2983 left-hand column first full paragraph, fig. 1-7 and discussion * [I] 1,11,12,15 DOI: http://dx.doi.org/10.4155/tde.14.92 | [A] - CARLA LUCIA ESPOSITO ET AL, "Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells", JOURNAL OF RNA I AND GENE SILENCING, GB, (20140101), vol. 10, ISSN 1747-0854, pages 500 - 506, XP055556137 [A] 1-4,8-15 * the whole document * | [A] - JIEHUA ZHOU ET AL, "Current Progress of RNA Aptamer-Based Therapeutics", FRONTIERS IN GENETICS, (20120101), vol. 3, doi:10.3389/fgene.2012.00234, ISSN 1664-8021, XP055082355 [A] 1-4,8-15 * the whole document * DOI: http://dx.doi.org/10.3389/fgene.2012.00234 | [A] - CINDY MEYER ET AL, "Cell-Specific Aptamers as Emerging Therapeutics", JOURNAL OF NUCLEIC ACIDS, (20110101), vol. 2011, doi:10.4061/2011/904750, pages 1 - 18, XP055556150 [A] 1-4,8-15 * the whole document * DOI: http://dx.doi.org/10.4061/2011/904750 | [A] - OMID C FAROKHZAD ET AL, "Nanoparticle-aptamer bioconjugates for cancer targeting", EXPERT OPINION ON DRUG DELIVERY, GB, (20060426), vol. 3, no. 3, doi:10.1517/17425247.3.3.311, ISSN 1742-5247, pages 311 - 324, XP055556152 [A] 1-4,8-15 * the whole document * DOI: http://dx.doi.org/10.1517/17425247.3.3.311 | [A] - YEH-HSING LAO ET AL, "Aptamer Nanomedicine for Cancer Therapeutics: Barriers and Potential for Translation", ACS NANO, US, (20150324), vol. 9, no. 3, doi:10.1021/nn507494p, ISSN 1936-0851, pages 2235 - 2254, XP055556155 [A] 1-4,8-15 * the whole document * DOI: http://dx.doi.org/10.1021/nn507494p | [XI] - CHAKRABARTI R ET AL, "A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 37, ISSN 0264-410X, (20050831), pages 4553 - 4564, (20050831), XP027651841 [X] 1-4,6,8,10,11 * abstract, p. 4554 right-hand column first and fourth full paragraphs, the paragraph bridging p. 4554 to p. 4555, p. 4555 left-hand column third full paragraph, paragraph bridging p. 4555 to p. 4556, results and discussion * [I] 7,9,12-15 | [XI] - LIU AIHONG ET AL, "Combination B7-Fc fusion protein treatment and Treg cell depletion therapy", CLINICAL CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20051201), vol. 11, no. 23, doi:10.1158/1078-0432.CCR-05-1411, ISSN 1078-0432, pages 8492 - 8502, XP002533977 [X] 1-4,6,8,10,11 * abstract, p. 8493 paragraph bridging the left- to the right-hand column, right-hand column first full paragraph, right-hand column fourth full paragraph, paragraph bridging p. 8493 to p. 8494, p. 8494left-hand column last full paragraph - p. 8497 left-hand column line 15, Fig. 1, 3-6 and 9 and discussion * [I] 7,9,12-15 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-05-1411 | [A] - DREW M. PARDOLL, "The blockade of immune checkpoints in cancer immunotherapy", NATURE REVIEWS. CANCER, GB, (20120401), vol. 12, no. 4, doi:10.1038/nrc3239, ISSN 1474-175X, pages 252 - 264, XP055415943 [A] 1-4,8-15 * the whole document * DOI: http://dx.doi.org/10.1038/nrc3239 | [A] - AINA O H ET AL, "THERAPEUTIC CANCER TARGETING PEPTIDES", BIOPOLY, JOHN WILEY & SONS, INC, US, (20020101), vol. 66, no. 3, doi:10.1002/BIP.10257, ISSN 0006-3525, pages 184 - 199, XP009006022 [A] 1-4,8-15 * the whole document * DOI: http://dx.doi.org/10.1002/bip.10257 | International search | [Y]US2009123467 (BEDI ATUL [US], et al) [Y] 1-6, 30, 31, 40-44, 63, 64, 66, 85 * abstract, [0017], [0024], [0030], [0031], [0103], [0299], [0420], [0550] *; | [Y]US2011081354 (KORMAN ALAN [US], et al) [Y] 1-6, 30, 31, 40-44, 63, 64, 66, 85 * abstract, para [0316] *; | [A] - WUELLNER et al., "Expanding the concept of chemically programmable antibodies to RNA-aptamers: a novel class of chemically programmed biotherapeutics", Angew Chem Int Ed Engl, (20100000), vol. 49, no. 34, pages 5934 - 5937, XP055362316 [A] 1-6, 30, 31, 40-44, 63, 64, 66, 85 * . Entire Document * DOI: http://dx.doi.org/10.1002/ange.201001736 |